Pricing of orphan drugs in oncology and rare diseases
Objective: The objective of this paper is to determine an upper price limit for an orphan drug by taken a broader perspective and, including also other monetary and non-monetary values for the society. Methods: This model is based on the expected free cash flows and the required minimum rate of retu...
Saved in:
| Main Authors: | Mark Nuijten, Stefano Capri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2020.1838191 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pricing Zolgensma – the world’s most expensive drug
by: Mark Nuijten
Published: (2022-12-01) -
An integrated valuation model for payer and investor
by: Mark Nuijten, et al.
Published: (2022-12-01) -
Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01) -
Analysing criteria for price and reimbursement of orphan drugs in Spain
by: Xavier Badia, et al.
Published: (2019-07-01) -
A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01)